KarX-EC + KarXT for autistic disorder

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 20 Feb 2026: Trial registered, NCT07424404
  2. 7 Apr 2026: Trial started, NCT07424404

The trials

NCT07424404: A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents

State
Under way
Phase
Phase 3
People
400 planned
Started
7 Apr 2026
Primary completion
8 Mar 2030
Arms
Administration of KarXT + KarX-EC for Autism Spectrum Disorder
Results
None posted
  1. 20 Feb 2026: Trial registered
  2. 7 Apr 2026: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.